TransCode Therapeutics Inc. (NASDAQ:RNAZ) Sees Significant Drop in Short Interest

TransCode Therapeutics Inc. (NASDAQ:RNAZ) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 34,446 shares, a decline of 34.8% from the June 30th total of 52,823 shares. Based on an average trading volume of 41,287 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.3% of the shares of the company are short sold.

TransCode Therapeutics Price Performance

Shares of RNAZ opened at $5.25 on Friday. The firm’s 50 day moving average is $6.35 and its 200-day moving average is $8.02. TransCode Therapeutics has a 12-month low of $3.82 and a 12-month high of $20.99. The stock has a market capitalization of $5.57 million, a P/E ratio of -0.10 and a beta of 1.23.

TransCode Therapeutics (NASDAQ:RNAZ) last released its earnings results on Friday, May 15th. The company reported ($21.28) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.